Rexahn and Korea Research Institute of Chemical Technology Form Licensing Partnership
Rexahn Pharmaceuticals, Inc. announced that it has entered into a licensing partnership with Korea Research Institute of Chemical Technology (“KRICT”) regarding the development of a synthetic process for Quinoxalines compounds. Research has demonstrated that Quinoxalines provide selective toxicity towards hypoxic cells - cells found in solid tumors and that are resistant to anticancer drugs and radiation therapy. This makes Quinoxaline-based drugs a potential potent treatment for solid tumors.
Dr. Chang Ahn, Rexahn’s Chairman and CEO, commented, “KRICT is a world-class research institute and partnership with KRICT will further enrich our growing pre-clinical drug pipeline devoted to new therapies that change treatment paradigms in cancer and CNS.” Dr. Ahn added, “The Quinoxaline family of compounds is very promising, and we expect to bring Quinoxaline-based drugs into the clinical trial process and ultimately to market.”
Under the terms of the agreement, Rexahn will acquire all intellectual properties related to Quinoxaline-Piperazine derivatives that were synthesized under a previous Joint Research Agreement, by exercising its option to receive an exclusive license to use, develop and commercially exploit the intellectual properties.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
